This seems to be a promising approach for faster drug development at lower cost!
"... BenchSci has launched a new AI software that aims to expedite preclinical phase drug development pipelines by extracting biological insights underlying disease.
The end-to-end SaaS (software as a service) platform, ASCEND, enables the discovery of biological connections, reduces unnecessary experiments, and uncovers risks at early stages. ... uses .. machine-learning technology to extract experimental evidence from secure internal and open external sources. The platform uses curated ontology datasets and compares experimental outcomes. This enables the software to create an evidence-based “map” of the biological mechanisms underlying different diseases.
... guide preclinical research by enhancing target selection, conducting due diligence, generating hypotheses, developing optimal investigative approaches, designing experiments, and identifying safety and efficacy risks to support IND (investigational new drug) submissions for clinical translations.
... incorporates publicly available scientific data from over 15 million published experiments and proprietary data generated by client companies that is securely available to respective customers. This approach helps R&D scientists understand the biological feasibility of new or existing lines of investigation and identify optimal approaches for testing hypotheses. ..."
No comments:
Post a Comment